A waterproof, gel-free wireless ECG patch invented at RMIT University and developed by Aussie start-up Lubdub has entered a clinical trial in Western Australia this week, tracking heart rhythm continuously for up to 14 days while patients go about daily life — promising the detail of a medical-grade Holter monitor without the clinic walls.
The trial, starting this week at Midlands Medical Specialists in Perth, will enroll patients who have already been prescribed a Holter monitor. Participants will wear the prototype patch so researchers can gather the evidence needed for further development and a push toward regulatory approval.
Why it matters: conventional Holter monitors typically record for only a day or two, and intermittent symptoms such as palpitations often go uncaught. A 14-day patch that works during ordinary activity could close that diagnostic window — and, according to early testing, do it with far cleaner data.
Prototype Patch Monitors Heart for 14 Days
- An ECG (electrocardiogram) records the electrical signals that make your heart beat; a Holter monitor is a portable version worn for 24–48 hours.
- This patch does the same job for up to 14 days, is waterproof, and needs no conductive gel — the sticky paste that traditional electrodes require.
- It is still a prototype in clinical testing; it is not yet approved, and patients should not change their monitoring plans based on this news.
Eighteen-Times Cleaner Signals, Claimed in Early Testing
Earlier testing in healthy volunteers found the prototype comfortable to wear and produced promising results.
“The flexible sensors make better contact with the skin than those used in traditional Holter monitors,” said RMIT Professor and Lubdub co-founder Sharath Sriram. “As a result, the data collected by the patch was 18-times cleaner compared with the traditional Holter monitors.”
Signal quality matters clinically. Noisy ECG data — distorted by motion, poor skin contact or drying gel — forces technicians into time-consuming manual cleanup before a cardiologist can read the rhythm. Sriram said the patch could let the same workforce produce reports for up to 85% more patients before tools like artificial intelligence are even added.
Cardiovascular Disease: The Diagnostic Gap It Targets
The clinical rationale is stark. Cardiovascular disease is responsible for roughly a third of deaths globally and nearly a quarter in Australia, Sriram noted, yet early symptoms are frequently missed.
“The majority of heart failure diagnoses and hospital admissions are unplanned and occur in emergency situations, with many patients reporting symptoms for years earlier,” Sriram said. “Our innovation is about simpler and more effective screening, because prevention is better than cure.”
Long-term rhythm monitoring is a standard tool for detecting arrhythmias — abnormal heart rhythms such as atrial fibrillation — that may appear only sporadically.
Extending monitoring from days to two weeks increases the chance of capturing an event, which is why extended-duration patches have drawn attention from cardiologists in the United States and Europe as well. The World Health Organization’s cardiovascular diseases fact sheet identifies these conditions as the leading cause of death worldwide.
RMIT Licenses IP to Lubdub Start-Up
RMIT University has licensed the intellectual property for the ECG patch and a related biomarker invention to Lubdub, which is building toward a combined platform of three technologies: wearable ECG monitoring, non-invasive cardiac biomarker testing, and wearable ultrasound imaging — a “heart health in a box” concept intended to replace a fragmented diagnostic journey spread across multiple appointments, specialists and facilities.
Momentum is financial as well as scientific. The Heart Foundation named Lubdub one of its 10 most promising heart health projects for 2026, and in September the company announced an oversubscribed $6 million seed funding round — double its original $3 million target — backed mainly by physicians and heart specialists.
For co-founder and director Nikhilesh Bappoo, the mission is personal. His father suffered a heart attack in Perth a few years ago and received timely specialist care; Bappoo grew up in Mauritius, where he says access would have been far more limited.
“Had it happened there, the outcome could have been very different,” Bappoo said.
RMIT’s ongoing partnership includes research grants and contracts plus access to pilot manufacturing facilities at its Discovery to Device program. Distinguished Professor Calum Drummond AO, the university’s Deputy Vice-Chancellor Research and Innovation, said the licensing agreement showed how university research could be translated into practical products.
“Lubdub is focused on making a real difference to heart health through cutting-edge electronics invented right here at RMIT,” Drummond said.
How the Patch Compares With Today’s Holter Monitors
| Feature | Traditional Holter monitor | Lubdub wireless patch (prototype) |
|---|---|---|
| Conductive gel required | Yes | No (gel-free) |
| Waterproof | Generally no | Yes |
| Signal quality in early testing | Baseline | Reported 18 times cleaner |
| Regulatory status | Established, approved | Prototype, in clinical trial |
One caution on the numbers: the 18-times signal improvement comes from early testing in healthy volunteers, not from the patient trial now underway. Whether it holds in people with arrhythmias, skin conditions or higher body-mass variation — all factors that degrade skin-electrode contact — is exactly what the Perth trial is designed to test. Neither source reports the trial’s sample size, a gap that will matter when regulators assess the evidence.
What Regulatory Approval Would Take, Here and Abroad
The trial’s stated purpose is to gather evidence supporting further development and potential regulatory approval. In Australia, that path runs through the Therapeutic Goods Administration; a US market entry would require Food and Drug Administration clearance, and European access would involve CE marking under EU medical device rules.
Extended-wear ECG patches are an established device category in the US, meaning Lubdub’s patch would face both a defined regulatory route and entrenched competitors — a reality the sources do not address directly.
Geographically, the equity argument may be the strongest one. Bappoo’s Mauritius reflection points to the broader problem the platform targets: cost, limited infrastructure, specialist shortages and long result waits that delay diagnosis in rural and remote regions — in Australia and well beyond it.
Device Unavailable; Seek Care for Heart Symptoms
This device is not available to the public and cannot be requested. Patients with prescribed Holter monitoring should follow their current plan. Anyone experiencing chest pain, unexplained breathlessness, fainting, or a racing or irregular heartbeat should seek medical care promptly — these symptoms warrant professional assessment regardless of what monitoring technology is used.
People with skin conditions or allergies to adhesives should raise them with their clinician before any extended wearable monitoring, since prolonged sensor contact can irritate skin.
The patch grew out of RMIT University, a public research university in Melbourne founded in 1887 as the Working Men’s College, a night school offering art, science and technology classes during Australia’s industrialisation.
The institution became the first Australian tertiary education provider awarded royal patronage, in 1954, and remains the only one in the country entitled to the “Royal” prefix. Now enrolling around 95,000 students, it is ranked 15th in the world for art and design in the QS World University Rankings.
Perth Trial Tests Patch in Real Patients
The Perth trial is the first real-world test of whether lab performance translates into patient care. Until results and regulatory decisions arrive, the patch remains a promising prototype — but one backed by physician investors, the Heart Foundation’s endorsement, and a diagnostic problem that kills roughly a third of people globally each year.
References
- News-Medical — “Wireless ECG patch aims to transform long-term heart rhythm monitoring”
- Nanowerk News — “Waterproof heart monitoring patch delivers cleaner ECG signals and enters clinical trial” (November 19, 2026)
- World Health Organization — Cardiovascular diseases fact sheet
Related reading
- Pancreatic Cancer Incidence Doubles in Men, Triples in Women Over 30 Years in France; Rise in Young Adults and Women Unexplained, Researchers Say
- SAME Director Alberto Crescenti Honored in Argentina’s Congress for Public Health Leadership
- Judge Rules Thomas Markle Mentally Fit to Stand Trial on Child Sexual Abuse Material Charge (archynewsy.com)